Business Description
ADC Therapeutics SA
NAICS : 325412
SIC : 2836
ISIN : CH0499880968
Description
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.88 | |||||
| Equity-to-Asset | -0.63 | |||||
| Debt-to-Equity | -0.64 | |||||
| Debt-to-EBITDA | -0.96 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -6.2 | |||||
| Beneish M-Score | -3.55 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 21.3 | |||||
| 3-Year EPS without NRI Growth Rate | 2.3 | |||||
| 3-Year FCF Growth Rate | 17.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 22.77 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 26.97 | |||||
| 9-Day RSI | 29.5 | |||||
| 14-Day RSI | 34.24 | |||||
| 6-1 Month Momentum % | 431.33 | |||||
| 12-1 Month Momentum % | 87.66 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.61 | |||||
| Quick Ratio | 4.35 | |||||
| Cash Ratio | 3.72 | |||||
| Days Inventory | 1519.07 | |||||
| Days Sales Outstanding | 124.95 | |||||
| Days Payable | 972.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.4 | |||||
| Shareholder Yield % | -2.68 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 93.52 | |||||
| Operating Margin % | -214.21 | |||||
| Net Margin % | -331.15 | |||||
| FCF Margin % | -218.77 | |||||
| ROA % | -53.98 | |||||
| ROIC % | -163.36 | |||||
| ROC (Joel Greenblatt) % | -771.5 | |||||
| ROCE % | -38.21 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4.11 | |||||
| EV-to-EBIT | -1.67 | |||||
| EV-to-EBITDA | -1.71 | |||||
| EV-to-Revenue | 3.22 | |||||
| EV-to-Forward-Revenue | 2.86 | |||||
| EV-to-FCF | -1.47 | |||||
| Earnings Yield (Greenblatt) % | -59.88 | |||||
| FCF Yield % | -45.35 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:ADCT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ADC Therapeutics SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 68.619 | ||
| EPS (TTM) ($) | -2.77 | ||
| Beta | 1.7 | ||
| Volatility % | 154.06 | ||
| 14-Day RSI | 34.24 | ||
| 14-Day ATR ($) | 0.348355 | ||
| 20-Day SMA ($) | 4.0955 | ||
| 12-1 Month Momentum % | 87.66 | ||
| 52-Week Range ($) | 0.35991 - 6.04 | ||
| Shares Outstanding (Mil) | 96.23 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ADC Therapeutics SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ADC Therapeutics SA Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
ADC Therapeutics SA Frequently Asked Questions
What is ADC Therapeutics SA(ADCT)'s stock price today?
The current price of ADCT is $3.43. The 52 week high of ADCT is $6.04 and 52 week low is $0.36.
When is next earnings date of ADC Therapeutics SA(ADCT)?
The next earnings date of ADC Therapeutics SA(ADCT) is 2024-08-08 Est..
Does ADC Therapeutics SA(ADCT) pay dividends? If so, how much?
ADC Therapeutics SA(ADCT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers